Literature DB >> 27666322

Polysaccharide isolated from the liquid culture broth of Inonotus obliquus suppresses invasion of B16-F10 melanoma cells via AKT/NF-κB signaling pathway.

Ki Rim Lee1, Jong Seok Lee2, Sarah Lee2, Youn Kyoung Son2, Ga Ryun Kim2, Ye Chan Sim1, Jeong Eun Song1, Suk-Jin Ha1, Eock Kee Hong1.   

Abstract

A number of polysaccharides exhibit pharmacological activities. Polysaccharides derived from Inonotus obliquus (PLIO) appear to have various potential pharmacological properties, including anti‑tumor activity. However, the molecular mechanisms underlying these properties remain to be elucidated. The present study investigated the anti‑metastatic potential of PLIO and the underlying signaling pathways in B16‑F10 murine melanoma cells using the MTT colorimetric assay, in vitro migration and invasion assays, and flow cytometric and western blot analyses. PLIO inhibited the invasion of B16‑F10 cells and suppressed the expression of matrix metalloproteinases. PLIO treatment inhibited nuclear factor‑κB (NF‑κB) nuclear translocation in B16‑F10 cells. In addition, PLIO treatment inhibited the phosphorylation of c-Jun N‑terminal kinases and AKT. These results suggest that PLIO may suppress the invasion of highly metastatic melanoma cells via inhibition of the AKT/NF-κB signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27666322     DOI: 10.3892/mmr.2016.5771

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

Review 1.  Recent Developments in Inonotus obliquus (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application.

Authors:  Yangpeng Lu; Yanan Jia; Zihan Xue; Nannan Li; Junyu Liu; Haixia Chen
Journal:  Polymers (Basel)       Date:  2021-04-29       Impact factor: 4.329

2.  In Vitro Immunomodulatory Effects of Inonotus obliquus Extracts on Resting M0 Macrophages and LPS-Induced M1 Macrophages.

Authors:  Dayue Shen; Yating Feng; Xilan Zhang; Jing Liu; Le Gong; Hui Liao; Rongshan Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-21       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.